logo
  

Cadence Design Systems Lifts FY22 Outlook

While reporting its third-quarter results on Monday, Cadence Design Systems (CDNS) lifted its outlook for the full year 2022.

For the full year 2022, the company now expects earnings of $2.71 to $2.75 per share, adjusted earnings of $4.20 to $4.24 per share and revenues of $3.532 billion to $3.552 billion.

Previously, the company expected earnings of $2.59 to $2.65 per share, adjusted earnings of $4.06 to $4.12 per share and revenues of $3.470 billion to $3.510 billion.

Analysts polled by Thomson Reuters currently estimate earnings of $4.12 per share and revenues of $3.50 billion. Analysts' estimates typically exclude one-time items.

For the fourth quarter, the company expects earnings of $0.50 to $0.54 per share, adjusted earnings of $0.89 to $0.93 per share and revenues of $870 million to $890 million. Analysts currently estimate earnings of $0.89 per share and revenues of $866.61 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
RELATED NEWS
Follow RTT